Pregabalin
Product Images NDC 55700-904

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 55700-904). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Quality Care Products, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

1

Pregabalin 300 mg capsule bottle label with a count of 60 capsules, labeled as prescription only and stating each capsule contains Pregabalin. Packaged and distributed by Quality Care Products, LLC, with manufacturer ScieGen Pharmaceuticals, Inc. The label includes storage information, habit-forming warning, GTIN, NDC 55700-904-60, and space for serial, lot, and expiration date.*

FDA Label Image

Figure 1 (Pregabalin Fig01)

A line graph depicting percent of patients improved versus percent improvement in pain from baseline, comparing Pregabalin doses of 25 mg, 100 mg, and 200 mg three times a day against placebo. The graph shows the higher doses of Pregabalin generally associated with greater patient improvement in pain.*

FDA Label Image

Figure 2 (Pregabalin Fig02)

A line graph showing the percent of patients improved versus percent improvement in pain from baseline. The graph compares Pregabalin 100 mg three times a day to placebo, with Pregabalin showing a higher percentage of patient improvement across various thresholds of pain improvement.*

FDA Label Image

Figure 3 (Pregabalin Fig03)

A line graph showing percent of patients improved versus percent improvement in pain from baseline for Pregabalin at 300 mg, 150 mg, 75 mg twice a day doses, and placebo. The graph compares efficacy across these doses, with percent improvement on the x-axis and percent of patients improved on the y-axis.*

FDA Label Image

Figure 4 (Pregabalin Fig04)

A line graph showing the percentage of patients improved versus percent improvement in pain from baseline for Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, and placebo groups. The y-axis represents the percent of patients improved, and the x-axis shows the percent improvement in pain from baseline.*

FDA Label Image

Figure 5 (Pregabalin Fig05)

A line graph showing the percent of patients improved versus percent improvement in pain from baseline. It compares Pregabalin 100 mg three times a day, Pregabalin 50 mg three times a day, and placebo, illustrating patient response levels at varying degrees of pain improvement.*

FDA Label Image

Figure 6 (Pregabalin Fig06)

A bar chart comparing responder rates (%) in two separate studies, Study E1 and Study E3. The chart shows different dosing regimens including placebo and various Pregabalin doses in mg/day. Responders increase with dosage in both studies, with statistical significance noted versus placebo for multiple doses.*

FDA Label Image

Figure 7 (Pregabalin Fig07)

A line graph depicting seizure reduction as median percent change from baseline on the y-axis versus dose in mg/day on the x-axis. The graph compares four studies (E1 BD, E2 TID, E3 BD, and E3 TID) with data points and significant p-values displayed, illustrating seizure reduction patterns at various pregabalin doses, including placebo at zero dose.*

FDA Label Image

Figure 9 (Pregabalin Fig08)

A line graph depicting the percent of patients improved by percent improvement in pain from baseline for Pregabalin at 300mg, 450mg, and 600mg daily doses compared to placebo. The graph shows four lines representing each dose and placebo, with the x-axis labeled as percent improvement in pain and the y-axis as percent of patients improved.*

FDA Label Image

Figure 10 (Pregabalin Fig09)

A line graph comparing the estimated percentage of subjects without LTR over time (days) between Pregabalin and placebo groups. The Y-axis shows the percentage from 0% to 100%, and the X-axis shows days from 0 to 180. The solid line represents Pregabalin, showing a higher percentage of subjects without LTR over time compared to the dashed line for placebo.*

FDA Label Image

Figure 11 (Pregabalin Fig10)

A line graph comparing the percent of subjects improved over time from baseline to Week 12 BOCF in two groups: Pregabalin and Placebo. The x-axis represents percent improvement from baseline to Week 12, and the y-axis shows the percent of subjects improved, with Pregabalin consistently showing higher improvement percentages than Placebo.*

FDA Label Image

Figure 12 (Pregabalin Fig11)

A line graph depicting the percentage of subjects improved from baseline to week 16 BOCF, comparing Pregabalin and Placebo. The x-axis represents percent improvement ranging from greater than 0 to 100, while the y-axis shows the percent of subjects improved. Two lines show higher improvement rates for Pregabalin compared to Placebo across the range.*

FDA Label Image

Cockcroft And Gault Equation (Pregabalin Formula)

A formula depiction for calculating creatinine clearance (CLcr) based on age, weight, and serum creatinine, with an adjustment factor for female patients. The formula includes variables for age in years, weight in kilograms, serum creatinine in mg/dL, and a multiplication factor of 0.85 for females.*

FDA Label Image

Chemical Structure (Pregabalin Str)

Chemical structure of the active ingredient Pregabalin, showing its molecular arrangement including amino and carboxyl functional groups.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.